Becotatug Vedotin and Pucotenlimab

DRUG2 trials

Sponsors

West China Hospital, Tianjin Medical University Cancer Institute and Hospital

Conditions

Hypopharyngeal Squamous Cell CarcinomaNasopharyngeal Cancinoma (NPC)

Phase 2

MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial

Not yet recruitingNCT07381699

West China HospitalNasopharyngeal Cancinoma (NPC)

Start: 2026-02-01End: 2030-02-01Target: 30Updated: 2026-02-13

Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma

RecruitingNCT07665190

Tianjin Medical University Cancer Institute and HospitalHypopharyngeal Squamous Cell Carcinoma

Start: 2026-07-01End: 2030-12-31Target: 52Updated: 2026-07-16

Related Papers

Becotatug vedotin plus pucotenlimab as first-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial.

Journal of Clinical Oncology2026-05-28